Business Wire

Diversified Nano Solutions Corp. and Screen Graphic Solutions Co., Ltd. Enter into a Strategic Relationship to Offer Revolutionary INKcrypt® DNA-Identity Ink and x-nano™ Special Effect Inkjet Inks for Screen Inkjet Platforms

Jaa

Diversified Nano Solutions Corporation (DNSC) and Screen Graphic Solutions Co, Ltd. (Screen) announce a strategic cooperation to offer revolutionary INKcrypt® anti-counterfeit solutions and x-nano™ special effect digital inkjet inks for Screen inkjet platforms. At PRINT17, Screen will demonstrate DNSC inkjet solutions (MICR and invisible UV fluorescent inks) with Truepress Jet520NX at booth 2613, September 10-14, 2017, in Chicago.

DNSC specializes in developing and manufacturing security ink, high-performance black & color ink, MICR ink, special effect inks, and associated fluids for digital printing platforms, which complements Screen’s focus on developing, manufacturing and marketing best-in-class Inkjet presses to clients worldwide.

“Our strategic cooperation with DNSC will allow Screen accelerated expansion and penetration of existing and new market opportunities for its portfolio of high performance digital inkjet platforms in particular related to graphics, security, finance (MICR), transpromo, and a fast growing demand in anti-counterfeit solutions,” said Seiichi Nakao, Global Business Director of Continuous HSI printers. “Screen’s family of Truepress Jet520 HD, ZZ, EX and NX, high speed, mono and high resolution full color inkjet presses are ideally positioned to support any market demand most competitively. In addition to conventional ink variations, we will be able to strongly promote the expansion of applications of inkjet presses.”

Bruce Carnes, Director of Business Development, added, “We are pleased with our opportunity to collaborate with Screen, a leading inkjet system manufacturer and famous brand in the industry, to jointly bring new inkjet output possibilities to users worldwide.”

Ideally suited for Screen inkjet platforms and a patent-pending industry innovation is DNSC’s revolutionary INKcrypt® technology, which integrates with inkjet and other fluid dispensing platforms. Users are now able to distinguish documents and/or products based on unique ink-identity, which can be authenticated on the spot using www.inkcryptink.com and smart devices. INKcrypt® provides item tracing, complete supply chain transparency, and elimination of fraud and counterfeiting. The INKcrypt® technology is based on unique DNA-identity markers, customized for each user, which can be added without changing the ink’s or fluid’s physical properties. INKcrypt® protects consumers and businesses from fraud, complete theft of product value, and health risks associated with counterfeiting, while brand owners prevent loss and strengthen customer confidence and loyalty.

Screen’s inkjet systems will be fully INKcrypt® compliant and support DNSC’s x-nano™ ink portfolio, including:

MICR ink (K-Ink Series), invisible UV fluorescent color, infrared-absorbing (I-Ink Series), and special inks. DNSC inks, customized for Screen systems, will be available through Screen’s sales channels worldwide. Screen and DNSC jointly are ideally positioned to help users create differentiated, high-value output through personalization using x-nano™ special effect inks such as magnetic (MICR), invisible fluorescent and security inks for digital inkjet platforms.

About Screen

SCREEN Graphic Solutions Co., Ltd. (SCREEN GA) is a core group company of SCREEN Holdings Co., Ltd. (formerly Dainippon Screen Mfg. Co., Ltd.) and is also one of the world’s leading manufacturers of graphic arts equipment. SCREEN GA has utilized the image processing and inkjet technologies developed by the SCREEN Group over many decades to create the Truepress Jet series of inkjet POD presses, which includes roll-fed, UV label, large size and sheet-fed systems. The comprehensive lineup also features market-leading products such as EQUIOS universal workflow and the PlateRite series of CtP devices.

About DNSC

Diversified Nano Solutions Corporation (DNSC), based in San Diego, California, specializes in developing and manufacturing nano materials and fluids used in high-performance functional inks for digital printing, unique customer applications, research and surface treatments. DNSC has developed an extensive product line of inks known as x-nano™, providing a range of solutions that utilize nanoparticles in long-term stable suspension, including MICR inks (Magnetic Ink Character Recognition), invisible color (RGB) fluorescent inks (UV [250-365nm] / IR [780-1050nm]), special pigmented/hybrid inks, and special pigmented/hybrid inks for food grade and non-food applications. These digital inks address drop-on-demand inkjet applications based on thermal and piezo print heads using aqueous, oil, energy curable (UV/LED) and eco-solvent-based inks. The company maintains high volume manufacturing facilities in Europe and the USA. DNSC’s inks are suitable for systems and platforms offered by various inkjet printer vendors and inkjet head manufacturers.

DNSC will be presenting INKcrypt® inks and its line of black & color, magnetic, invisible, special effect, and security inks for the world’s leading inkjet print systems in the desktop, commercial and industrial inkjet space.

Visit booth 854 and discover DNSC digital INKS unlimited!

Contact information

Diversified Nano Solutions Corporation
Linda Meyers
US Headquarters: +1.858.924.1005
EMEA: +41.41 874 08 50
info@diversifiednano.com
www.diversifiednano.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Pierre Fabre & Array BioPharma Announce a 62% Observed OS at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO GI Congress23.6.2018 14:00Tiedote

Not intended for UK- and US-based media Pierre Fabre and its partner Array BioPharma Inc. today announced updated safety and efficacy results, including OS, from the safety lead-in of the Phase 3 BEACON CRC trial evaluating the triplet combination of encorafenib, a BRAF inhibitor, binimetinib, a MEK inhibitor and cetuximab, an anti-EGFR antibody, in patients with BRAF V600E -mutant metastatic colorectal cancer (CRC). The results showed that, at the time of analysis, the OS data were fully mature through 12.6 months and that the median OS had not yet been reached. The one-year overall survival rate for this cohort was 62%. These data were presented in an oral presentation on Saturday, June 23, at the ESMO 20th World Congress on Gastrointestinal Cancer in Barcelona, Spain. The median progression-free survival (mPFS) for patients treated with the triplet was 8 months [95% CI 5.6-9.3] and is similar between patients receiving one prior line of therapy and patients receiving two prior lines

Compelling Data for LONSURF® (trifluridine/tipiracil) in Metastatic Colorectal Cancer Presented at ESMO’s World Congress on Gastrointestinal Cancer by Servier and Taiho23.6.2018 11:10Tiedote

Servier and Taiho Pharmaceutical Co., Ltd. today announced that the TASCO-1 trial demonstrated promising results for LONSURF® (trifluridine/tipiracil) in combination with bevacizumab in patients with previously untreated metastatic colorectal cancer (mCRC) who are not suitable for intensive treatment, with a median progression-free survival (PFS) of 9.2 months (ranging from 7.6 to 11.5 months). A second non-comparative arm in the trial, evaluated the outcome of patients treated with the current standard of care of capecitabine in combination with bevacizumab. The median PFS of this arm was 7.8 months (ranging from 5.5 to 10.1 months). “Colorectal cancer is the third most common cancer in the world. While there has been some progress in treatment, there are still few options for patients with metastatic disease who are not suitable for intensive treatment,” said Professor Eric Van Cutsem, Head of Digestive Oncology at the University of Leuven, Belgium. “These compelling results suggest

Softomotive and Accelerate RPA Partner to Help Enterprises Achieve Faster Time to Value from RPA22.6.2018 18:13Tiedote

Softomotive, a world–class Robotic Process Automation (RPA) technology provider offering best time to value and affordability for all sizes and types of enterprises, is pleased to announce a strategic partnership with AccelerateRPA, a high calibre professional services provider of trained and certified RPA Consultants within Robotic Process Automation. This partnership means that customers and end users of Softomotive’s software, will have additional knowledgeable and professional guidance available to help achieve significant value quickly from their investment in RPA. Companies who are looking to implement Softomotive’s RPA product suite (WinAutomation and ProcessRobot software) will now have direct access to AccelerateRPA’s highly skilled consultants and Developers. Further, AccelerateRPA has also become a licensed reseller of Softomotive’s products, offering customers a single point of contact for delivering both RPA software and services. Ashley Hudson, Director of AccelerateRPA,

Ascend Performance Materials Announces Price Increase for Intermediate Materials22.6.2018 17:00Tiedote

Ascend Performance Materials announced today a price increase for its intermediate materials. The price increase will take effect globally on July 1, 2018, and includes the following terms: Material Price Increase Terms Hexamethylene diamine (HMD) $0.17/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Acrylonitrile (AN) $0.20/lb. • As contracts allow. • Non-contract business – price determined on an order-by-order basis. Customers should contact their local sales representative for additional information. About Ascend Performance Materials Ascend Performance Materials is a global premium provider of high-quality plastics, fibers and chemicals and is the world’s largest integrated producer of PA66 resin. Headquartered in Houston, Texas, Ascend has eight global locations, including five fully-integrated manufacturing facilities located in the southeastern United States, all dedicated to the innovation and safe production of nylon 6,6. With

Different Countries, Different Customs: Get Ready for the Motorbike Holidays with Moto-tyres.co.uk22.6.2018 16:41Tiedote

Pack your bags, close the boot and get away on holiday? When you start your holidays on a motorcycle, you usually have to consider a few things more when getting ready for your trip. The right preparation is therefore a must. So that nothing stands in the way of a smooth journey, Moto-tyres.co.uk has put together some tips for your next trip. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180622005345/en/ Different countries, different customs: get ready for the motorbike holidays with Moto-tyres.co.uk (Photo: Business Wire) Whether a weekend trip or extended adventure, it all depends on the right equipment. Functional clothing, protectors and rain protection are a must on long trips. Wearing a suitable motorcycle helmet is a legal requirement almost everywhere. However, there are also very different rules and regulations for motorbike equipment and accessories depending on the destination, and you should familiarise yoursel

Boehringer Ingelheim bolsters biologics research and development with 230 million euro investment in new development center22.6.2018 15:00Tiedote

Today Boehringer Ingelheim announced a 230 million euro investment into a new Biologicals Development Center (BDC) at the company’s Research and Development site in Biberach, Germany during the foundation stone laying for the new center. “The BDC is another key building block supporting the company’s long-term strategy for increasing the pipeline’s share of biologicals. This is particularly driven by two of our core areas, immune oncology and immunology,” says Dr. Fridtjof Traulsen, Corporate Senior Vice President Development at Boehringer Ingelheim. “The share of new biological entities in Boehringer Ingelheim’s research pipeline has been consistently increasing over the past few years and has now reached forty percent.” The BDC will help to maximize synergies by integrating biologicals analytical and process development as well as manufacturing for clinical studies into one seamless unit, while at the same time increasing development capacity. Following a staggered launch beginning i

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme